Sorrento Therapeutics, Inc.
Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody

Abstract:

The present disclosure provides compositions and methods comprising a first antibody comprising a fully human anti-CD47 antibody and a second antibody comprising an Fc portion that binds an Fc.gamma. receptor on an effector cell. In various embodiments the anti-CD47 antibody used in the methods and compositions exhibits a low level of binding to red blood cells and does not induce hemagglutination even at high concentrations of antibody. In some embodiments, the second antibody comprises a tumor-targeting antibody including an antibody that binds CD20, PD-L1, CD38 or SLAMF7 antigens. The combination of the fully human anti-CD47 antibody and the second antibody can decrease cancer burden in a subject.